|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
2
|
Fu ZT, Guo XL, Zhang SW, Zheng RS, Zeng
HM, Chen R, Wang SM, Sun KX, Wei WW and He J: Statistical analysis
of incidence and mortality of prostate cancer in China, 2015.
Zhonghua Zhong Liu Za Zhi. 42:718–722. 2020.(In Chinese).
PubMed/NCBI
|
|
3
|
Sekhoacha M, Riet K, Motloung P, Gumenku
L, Adegoke A and Mashele S: Prostate cancer review: Genetics,
diagnosis, treatment options, and alternative approaches.
Molecules. 27:57302022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watson PA, Arora VK and Sawyers CL:
Emerging mechanisms of resistance to androgen receptor inhibitors
in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross RW, Xie W, Regan MM, Pomerantz M,
Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW and Oh
WK: Efficacy of androgen deprivation therapy (ADT) in patients with
advanced prostate cancer: Association between Gleason score,
prostate-specific antigen level, and prior ADT exposure with
duration of ADT effect. Cancer. 112:1247–1253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garje R, Chennamadhavuni A, Mott SL,
Chambers IM, Gellhaus P, Zakharia Y and Brown JA: Utilization and
outcomes of surgical castration in comparison to medical castration
in metastatic prostate cancer. Clin Genitourin Cancer.
18:e157–e166. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patke R, Harris AE, Woodcock CL, Thompson
R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson
BD, et al: Epitranscriptomic mechanisms of androgen signalling and
prostate cancer. Neoplasia. 56:1010322024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kolvenbag GJ and Nash A: Bicalutamide
dosages used in the treatment of prostate cancer. Prostate.
39:47–53. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scott LJ: Enzalutamide: A review in
Castration-resistant prostate cancer. Drugs. 78:1913–1924. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clegg NJ, Wongvipat J, Joseph JD, Tran C,
Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, et al:
ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer
Res. 72:1494–1503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Li H, Liu B, Wang X, Zhou W, Wu G
and Xu C: Identification and validation of MSMB as a critical gene
for prostate cancer development in obese people. Am J Cancer Res.
13:1582–1593. 2023.PubMed/NCBI
|
|
13
|
Chen X, Ma J, Wang X, Zi T, Qian D, Li C
and Xu C: CCNB1 and AURKA are critical genes for prostate cancer
progression and castration-resistant prostate cancer resistant to
vinblastine. Front Endocrinol (Lausanne). 13:11061752022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li H, Wang X, Zhai M, Xu C and Chen X:
Exploration of the influence of GOLGA8B on prostate cancer
progression and the resistance of castration-resistant prostate
cancer to cabazitaxel. Discov Oncol. 15:1522024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma J, Qin X, Le W, Chen X, Wang X and Xu
C: Identification of BBC3 as a novel indicator for predicting
prostate cancer development and olaparib resistance. Discov Oncol.
15:4962024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen X, Wu Y, Wang X, Xu C, Wang L, Jian
J, Wu D and Wu G: CDK6 is upregulated and may be a potential
therapeutic target in Enzalutamide-resistant castration-resistant
prostate cancer. Eur J Med Res. 27:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blum A, Wang P and Zenklusen JC: SnapShot:
TCGA-Analyzed tumors. Cell. 173:5302018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z,
Wang H, Yu Y, Yang C, Gao X, et al: A genomic and epigenomic atlas
of prostate cancer in Asian populations. Nature. 580:93–99. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chawla S, Rockstroh A, Lehman M, Ratther
E, Jain A, Anand A, Gupta A, Bhattacharya N, Poonia S, Rai P, et
al: Gene expression based inference of cancer drug sensitivity. Nat
Commun. 13:56802022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng
H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, et al: A
noncanonical AR addiction drives enzalutamide resistance in
prostate cancer. Nat Commun. 12:15212021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shah S, Carriveau WJ, Li J, Campbell SL,
Kopinski PK, Lim HW, Daurio N, Trefely S, Won KJ, Wallace DC, et
al: Targeting ACLY sensitizes castration-resistant prostate cancer
cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback
mechanism. Oncotarget. 7:43713–43730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled Protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Ma J, Xu C, Wang L, Yao Y, Wang X,
Zi T, Bian C, Wu D and Wu G: Identification of hub genes predicting
the development of prostate cancer from benign prostate hyperplasia
and analyzing their clinical value in prostate cancer by
bioinformatic analysis. Discov Oncol. 13:542022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Li H, Xu C, Wang X, Wu G, Li C and
Wu D: CYP19A1 is downregulated by BRD4 and suppresses
castration-resistant prostate cancer cell invasion and
proliferation by decreasing AR expression. Am J Cancer Res.
13:4003–4020. 2023.PubMed/NCBI
|
|
29
|
Paner GP, Stadler WM, Hansel DE, Montironi
R, Lin DW and Amin MB: Updates in the eighth edition of the
Tumor-Node-Metastasis staging classification for urologic cancers.
Eur Urol. 73:560–569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
31
|
Etzioni R, Tsodikov A, Mariotto A, Szabo
A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson
DF and Feuer E: Quantifying the role of PSA screening in the US
prostate cancer mortality decline. Cancer Causes Control.
19:175–181. 2008.PubMed/NCBI
|
|
32
|
Arsov C, Winter C, Rabenalt R and Albers
P: Current second-line treatment options for patients with
castration resistant prostate cancer (CRPC) resistant to docetaxel.
Urol Oncol. 30:762–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fradet Y: Bicalutamide (Casodex) in the
treatment of prostate cancer. Expert Rev Anticancer Ther. 4:37–48.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Armstrong AJ, Azad AA, Iguchi T,
Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A,
Alekseev B, Shore ND, et al: Improved survival with enzalutamide in
patients with metastatic hormone-sensitive prostate cancer. J Clin
Oncol. 40:1616–1622. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smith MR, Saad F, Chowdhury S, Oudard S,
Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H,
et al: Apalutamide treatment and Metastasis-free survival in
prostate cancer. N Engl J Med. 378:1408–1418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Z, Zhou C, Li X, Barnes SD, Deng S,
Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, et al: Loss of CHD1
Promotes heterogeneous mechanisms of resistance to AR-Targeted
therapy via chromatin dysregulation. Cancer Cell. 37:584–598.e11.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu
C, Russo JW, Liu M, Mota JM, Abida W, Linton E, et al: Tumor
Microenvironment-derived NRG1 promotes antiandrogen resistance in
prostate cancer. Cancer Cell. 38:279–296.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Spans L, Helsen C, Clinckemalie L, Van den
Broeck T, Prekovic S, Joniau S, Lerut E and Claessens F:
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B
prostate cancer cell lines. PLoS One. 9:e900022014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nie MJ, Pan XT, Tao HY, Xu MJ, Liu SL, Sun
W, Wu J and Zou X: Clinical and prognostic significance of MYH11 in
lung cancer. Oncol Lett. 19:3899–3906. 2020.PubMed/NCBI
|
|
40
|
Islam T, Rahman R, Gov E, Turanli B,
Gulfidan G, Haque A, Arga KY and Haque Mollah N: Drug targeting and
biomarkers in head and neck cancers: Insights from systems biology
analyses. OMICS. 22:422–436. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Xu P, Hao Y, Yu T, Liu L, Song Y
and Li Y: Interaction between DNMT3B and MYH11 via hypermethylation
regulates gastric cancer progression. BMC Cancer. 21:9142021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cho BS, Min GJ, Park SS, Park S, Jeon YW,
Shin SH, Yahng SA, Yoon JH, Lee SE, Eom KS, et al: Prognostic
values of D816V KIT mutation and Peri-transplant CBFB-MYH11 MRD
monitoring on acute myeloid leukemia with CBFB-MYH11. Bone Marrow
Transplant. 56:2682–2689. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura
I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, et
al: Prospective evaluation of prognostic impact of KIT mutations on
acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood
Adv. 4:66–75. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Alhopuro P, Karhu A, Winqvist R, Waltering
K, Visakorpi T and Aaltonen LA: Somatic mutation analysis of MYH11
in breast and prostate cancer. BMC Cancer. 8:2632008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang Y, Cao Q, Song Z, Ruan H, Wang K,
Chen K and Zhang X: The identification of key gene expression
signature in prostate cancer. Crit Rev Eukaryot Gene Expr.
30:153–168. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aurilio G, Cimadamore A, Mazzucchelli R,
Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni
M and Montironi R: Androgen receptor signaling pathway in prostate
cancer: From genetics to clinical applications. Cells. 9:26532020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Okumu LA, Bruinton S, Braden TD, Simon L
and Goyal HO: Estrogen-induced maldevelopment of the penis involves
down-regulation of myosin heavy chain 11 (MYH11) expression, a
biomarker for smooth muscle cell differentiation. Biol Reprod.
87:1092012. View Article : Google Scholar : PubMed/NCBI
|
